167 related articles for article (PubMed ID: 8747400)
1. Biomarkers in the ovary.
Berchuck A
J Cell Biochem Suppl; 1995; 23():223-6. PubMed ID: 8747400
[TBL] [Abstract][Full Text] [Related]
2. Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu.
Hakim AA; Barry CP; Barnes HJ; Anderson KE; Petitte J; Whitaker R; Lancaster JM; Wenham RM; Carver DK; Turbov J; Berchuck A; Kopelovich L; Rodriguez GC
Cancer Prev Res (Phila); 2009 Feb; 2(2):114-21. PubMed ID: 19174584
[TBL] [Abstract][Full Text] [Related]
3. Human ovarian cancer of the surface epithelium.
Berchuck A; Carney M
Biochem Pharmacol; 1997 Sep; 54(5):541-4. PubMed ID: 9337069
[TBL] [Abstract][Full Text] [Related]
4. Hereditary ovarian cancer.
Prat J; Ribé A; Gallardo A
Hum Pathol; 2005 Aug; 36(8):861-70. PubMed ID: 16112002
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
6. Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers.
Rhei E; Bogomolniy F; Federici MG; Maresco DL; Offit K; Robson ME; Saigo PE; Boyd J
Cancer Res; 1998 Aug; 58(15):3193-6. PubMed ID: 9699640
[TBL] [Abstract][Full Text] [Related]
7. [Genetic alterations in the genesis and development of ovarian cancer].
Okamoto A; Yokoyama S; Terashima Y
Gan To Kagaku Ryoho; 1992 Oct; 19(12):1971-6. PubMed ID: 1358031
[TBL] [Abstract][Full Text] [Related]
8. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer.
Kohler MF; Kerns BJ; Humphrey PA; Marks JR; Bast RC; Berchuck A
Obstet Gynecol; 1993 May; 81(5 ( Pt 1)):643-50. PubMed ID: 8469448
[TBL] [Abstract][Full Text] [Related]
9. The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.
Buller RE; Lallas TA; Shahin MS; Sood AK; Hatterman-Zogg M; Anderson B; Sorosky JI; Kirby PA
Clin Cancer Res; 2001 Apr; 7(4):831-8. PubMed ID: 11309330
[TBL] [Abstract][Full Text] [Related]
10. p16 overexpression: a potential early indicator of transformation in ovarian carcinoma.
Shigemasa K; Hu C; West CM; Clarke J; Parham GP; Parmley TH; Korourian S; Baker VV; O'Brien TJ
J Soc Gynecol Investig; 1997; 4(2):95-102. PubMed ID: 9101469
[TBL] [Abstract][Full Text] [Related]
11. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
12. Molecular biology of human ovarian cancer.
Chow SN; Chien CH; Chen CT
Int Surg; 1996; 81(2):152-7. PubMed ID: 8912082
[TBL] [Abstract][Full Text] [Related]
13. Clinical factors and biomarkers in ovarian tumors development.
Vrabie CD; Petrescu A; Waller M; Dina I
Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors.
Berchuck A; Kohler MF; Hopkins MP; Humphrey PA; Robboy SJ; Rodriguez GC; Soper JT; Clarke-Pearson DL; Bast RC
Gynecol Oncol; 1994 Feb; 52(2):232-6. PubMed ID: 7508877
[TBL] [Abstract][Full Text] [Related]
15. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma.
Leitao MM; Soslow RA; Baergen RN; Olvera N; Arroyo C; Boyd J
Gynecol Oncol; 2004 May; 93(2):301-6. PubMed ID: 15099937
[TBL] [Abstract][Full Text] [Related]
16. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.
Havrilesky LJ; Alvarez AA; Whitaker RS; Marks JR; Berchuck A
Gynecol Oncol; 2001 Dec; 83(3):491-500. PubMed ID: 11733961
[TBL] [Abstract][Full Text] [Related]
17. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas.
Smith CA; Pollice AA; Gu LP; Brown KA; Singh SG; Janocko LE; Johnson R; Julian T; Hyams D; Wolmark N; Sweeney L; Silverman JF; Shackney SE
Clin Cancer Res; 2000 Jan; 6(1):112-26. PubMed ID: 10656439
[TBL] [Abstract][Full Text] [Related]
18. Mutational spectrum of p53 mutations in primary breast and ovarian tumors.
Feki A; Irminger-Finger I
Crit Rev Oncol Hematol; 2004 Nov; 52(2):103-16. PubMed ID: 15501075
[TBL] [Abstract][Full Text] [Related]
19. [Germ-line mutation of BRCA1 in patients with breast and/or ovarian cancer in high risk families in Northern France].
Peyrat JP; Vennin P; Hornez L; Bonneterre J
Bull Cancer; 1997 Jan; 84(1):41-6. PubMed ID: 9180858
[TBL] [Abstract][Full Text] [Related]
20. No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers.
Aghmesheh M; Nesland JM; Kaern J; Dorum A; Edwards L; Byth K; Friedlander M; Jackson P; Tucker KM; Russell PJ
Gynecol Oncol; 2004 Dec; 95(3):430-6. PubMed ID: 15581943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]